POLARx™
Cryoablation System
Explore
*Only ablations with duration >60S included in ablation counts
Freedom from atrial arrhythmias
at follow-up (6 months) after using POLARx FIT
Major adverse events
including esophageal fistulas, persistent phrenic nerve palsy and PV stenosis
High-grade occlusion rate
resulting in either Grade 3 or Grade 4 occlusion level
POLAR ICE multicenter study
ANTARCTICA observational study
Acute PV isolation
Real-time PVI visualization
Freedom from recurrence
at 226 ± 150 days
Performance vs. existing cyroablation systems
Faster procedure time
vs. Arctic Front Advance
(61 min. vs 73 min.)
Faster to -40˚C
vs. Arctic Front Advance
(30 min. vs 48 min.)
Greater real-time isolation rate
vs. Arctic Front Advance
(70% vs 84%)
Procedural characteristics
Studies comparing POLARx™ and other cryoablation systems
Advance your understanding
Continue exploring POLARx technology on EDUCARE, Boston Scientific’s online medical education platform.
References:
1. Ellenbogen, et al. One-year outcomes of pulmonary vein isolation with a novel cryoballoon in 325 patients: primary results of the FROzEN-AF trial. Presented at: Heart Rhythm Society 2023; May 19-21, 2023; New Orleans, LA, USA.
2. Tilz R et al. Acute procedural characteristics, efficacy and safety of a novel cryoballoon for the tratement of aparoxysmal atrial fibrillation: Results from the POLAR-ICE study. EP Europace. 24:1, May 2022. doi.org/10.1093/europace/euac053.079
3. Heeger CH, Pott A, Sohns C, et al. Novel cryoballoon ablation system for pulmonary vein isolation: multicenter assessment of efficacy and safety-ANTARCTICA study. Europace. 2022 Dec 9;24(12):1917-25
4. Mojica J, Lipartiti F, Al Housari M, et al. Procedural safety and efficacy for pulmonary vein isolation with the novel POLARx™ Cryoablation System: A propensity score matched comparison with the Arctic Front™ Cryoballoon in the setting of paroxysmal atrial fibrillation. J Atr Fibrillation. 2021 Jun 30;14(1):20200455.
† Updated analysis with corrected data.